In recognition of World TB Day on March 24, organizations released their latest figures on tuberculosis in the U.S. and worldwide and called for more action to improve access to testing, care, and treatment, while 2 recent studies offered promise for shorter therapy.
HIVandHepatitis.com coverage of the 2015 Conference on Retroviruses and Opportunistic infections (CROI 2015), February 23-26, 2015, in Seattle.
Conference highlights include PrEP and HIV treatment as prevention, hepatitis C treatment for HIV/HCV coinfected people, new antiretroviral drugs, HIV cure research, HIV-related conditions, TB, Ebola virus, and access to care.
Researchers at the recent 2015 Conference on Retroviruses and Opportunistic Infections in Seattle discussed a variety of approaches to achieve a functional cure, or prolonged remission of HIV. Most experts expect that a combination of multiple approaches will be needed.
Among the most eagerly anticipated and well received news at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) last week in Seattle were a pair of reports showing that Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis, or PrEP, taken either daily or before and after sex, reduced the likelihood of HIV infection by 86%. In both studies, no one who took PrEP consistently became infected.